Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

CHMP Adopts Positive Opinion On ADASUVE - Quick Facts

RELATED NEWS
Trade ALXA now with 

Alexza Pharmaceuticals, Inc. (ALXA: Quote) and Grupo Ferrer Internacional, S.A., announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency adopted a positive opinion recommending that ADASUVE be granted European Union centralized marketing authorization.

The CHMP recommends ADASUVE be authorized in the EU for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder.

The CHMP positive opinion will now be forwarded to the European Commission. The company expects a decision from the European Commission in the first quarter of 2013.

Alexza filed the ADASUVE Marketing Authorization Application with the European Medicines Agency in October 2011.

Click here to receive FREE breaking news email alerts for Alexza Pharmaceuticals Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Specialty drugmaker Horizon Pharma plc (HZNP) on Friday managed to redomicile itself as an entity incorporated in Ireland following the completion of its $660 million acquisition of Vidara Therapeutics International plc. The deal will help it avoid paying the high rate of U.S. corporate taxes. The... Stocks showed a lack of direction over the course of the trading day on Friday after failing to sustain an initial upward move. Despite the choppy trading, the Dow once again managed to end the session at a new record closing high. The major averages turned in a mixed performance on the day. President Barack Obama delivered a statement Thursday evening thanking members of Congress for voting to approve legislation granting the U.S. military the authority to train and arm moderate Syrian rebels fighting against the terrorist group known as the Islamic State.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.